Rosuvastatin

Hyperlidipemia is a cardiovascular risk factor that is currently being undertreated in a high percentage of patients. Rosuvastatin is a new hydroxymethylglutaryl (HMG) CoA-reductase nhibitor that is more effective than the statins available until now and has a good safety profile. Thus, it may help...

Full description

Saved in:
Bibliographic Details
Published inPA AP no. 36; p. 38
Main Authors J. Honorato Pérez, I. Gil Aldea, V. Fernández Gallego
Format Journal Article
LanguageEnglish
Published Barcelona Ediciones Mayo 01.07.2004
Subjects
Cardiovascular disease
Clinical trials
Health risk assessment
Protease inhibitors
Online AccessGet full text

Cover

More Information
Summary:Hyperlidipemia is a cardiovascular risk factor that is currently being undertreated in a high percentage of patients. Rosuvastatin is a new hydroxymethylglutaryl (HMG) CoA-reductase nhibitor that is more effective than the statins available until now and has a good safety profile. Thus, it may help a greater number of patients to achieve compensation. Clinical trials performed to date with rosuvastatin have focused on different types of hyperlipidemia and some other entities such as the metabolic syndrome, comparing it with known statins. The pharmacokinetic characteristics of rosuvastatin make it convenient to administer, a circumstance that facilitates compliance, and its low drug interaction profile avoids complications in patients that are often taking other drugs as well. The effective treatment of hyperlipidemia is associated with a reduction in the incidence of ischemic heart disease and cerebrovascular accidents, which results in a marked cost savings.
ISSN:1139-1596